macrocyclic peptides action against the Hepatitis C virus.

A compound of formula (I) ** ** Formula wherein R1 is hydroxyl or NHSO2R11 R11 is alkyl (1-6C), (2-6C) alkenyl, (C3-7) cycloalkyl (C3-7) cycloalkyl- (C1-6) -, aryl, Het, aryl- (C1-4) - or Het-alkyl (C1-4) -; a) said alkyl (1-6C), alkenyl (2-6C), aryl, Het, cycloalkyl (C3-7) cycloalkyl- (C1-6) -, aryl- (1-4C) - and Het- (C1-4) - they are optionally substituted with one, two or three substituents independently selected from halogen, hydroxyl, cyano, nitro, (1-6C) alkyl, (C1-6) haloalkyl, -O- (C1-6) , -O- (C1-6) haloalkyl, -O-aryl, -C (= O) -C (C1-6), -C (= O) - NH2, -C (= O) -NH-alkyl ( C1-4), -C (= O) -N- ((1-4C)) 2, -NH2, -NH (C1-4) alkyl and -N ((1-4C)) 2; b) said cycloalkyl group (C3-7) may be optionally substituted with one more substituents independently selected from nitro, halogen, hydroxyl, cyano, -O-alkyl (C1-6), (C2-4) alkenyl, -O-halo cycloalkyl- (1-6C) alkyl, -NH2, -NH (C1-4) alkyl, -N- (alkyl (C1-4)) 2, trialkyl (C1- 6) alkylsilyl, R41, -C (= O) -R41, -C (= O) OR 41, -C (= O) N (R42) R41, -SO2R41 and -OC (= O) -R41; where R41 is each independently selected from: i) H, (C3-7) cycloalkyl (C4-7) alkyl Het or aryl (C1-4) -O-; ii) aryl and aryloxy, each optionally substituted with alkyl (1-6C); and iii) (C1-8) alkyl optionally substituted with one or more substituents selected from -O- irrespective alkyl (1-6C), hydroxyl, halogen, (2-10C) alkenyl, (2-10C) alkynyl, cycloalkyl (C3-7) cycloalkyl (C4-7) alkyl, aryl, Het, aryloxy and aryl-alkyl (C1-4) -O-, wherein each of said aryl and aryloxy is optionally substituted with (1-6C) alkyl ; and R42 is chosen from H and (C1-6) alkyl; or R11 is -N (R11a) (R11b), where R11a and R11b are independently selected from H, (1-6C) alkyl, (3-7C) cycloalkyl- (3-7C) cycloalkyl- (1-6C) -, aryl, aryl- (1-6C) -, Het and Het- (C1-4) -; wherein said (C1-6) alkyl, (C3-7) cycloalkyl- (C3-7) cycloalkyl- (C1-6) -, aryl, aryl (C1-6) -, Het and Het- ( 1-4) - they are optionally substituted with one or more substituents independently selected from halogen, alkyl (1-6C), hydroxyl, cyano, nitro, (C1-6) haloalkyl, -O- (C1-6) alkyl, -O haloalkyl (1-6C) -NH2, -NH (C1-4) alkyl, -N ((C1-4) alkyl) 2, -C (= O) -NH2, - C (= O) -NH (1-4C) alkyl, -C (= O) -N ((C1-4) alkyl) 2, -C (= O) -alkyl (1-6C), -COOH and -COO-alkyl (C1- 6); or R11a and R11b are connected with the nitrogen to which they are attached form a saturated monocyclic heterocycle or unsaturated 3 to 7 optionally fused members with at least another ring to form a heteropolycycle, whereby said heterocycle and heteropolycycle optionally containing from one to three additional heteroatoms independently selected from N, S and O and are sus45 tituidos optionally with one or more substituents independently selected from halogen, alkyl (1-6C), hydroxyl, cyano, nitro, (C1-6) haloalkyl, -O- (C1-8) alkyl, -O- (C1-6) haloalkyl, -NH2, -NH (1-4C) alkyl, -N ((C1-4) alkyl) 2, -C (= O) -NH2, - C (= O) -NH-alkyl (C1-4), -C (= O) -N ((C1-4) alkyl) 2, -C (= O) -C (C1- 6), -COOH and -COO (1-6C) alkyl; R2 is a group of formula: where R20 is H, OH, halogen or Y1-R20a, where Y1 is a bond, O, S or nr20b and wherein: R20a is selected from the group consisting of (C1-8), alkyl- (C1-6) -C≡N, alkenyl (C2-8), (C2-8) alkynyl and (C3-7) cycloalkyl, wherein each of said alkyl, alkenyl, alkynyl and cycloalkyl may be optionally substituted with one, two or three substituents independently selected from: halogen, alkyl (1-6C) optionally substituted with -O-alkyl (1-6C) or -O- (C3-6) cycloalkyl, (C3-7), -O alkyl (1-6C), Het, -O-cycloalkyl (C3-6), -NH2, -NH (C1-4) alkyl and -N ((1-4C)) 2; and R 20b is H, (1-6C) alkyl or (3-6C) cycloalkyl; and W is N; and the dotted line "a" is a double bond; or R20 is oxo and W is NR23, where R23 is H, alkyl (1-6C), alkenyl (2-6C) or alkynyl (2-6C); and the dotted line "a" is a single bond; R21 is halogen or Y2-R21a, where Y2 is a bond, O, S, SO or SO2, and R 21a is alkyl (1-6C), alkenyl (2-6C), alkynyl (2-6C), cycloalkyl (C3- 7) cycloalkyl- or (C3-7) cycloalkyl- (C1-6) -; R22 is H, -OH, -O- (C1-4) alkyl, -NH2, -NH (C1-4) alkyl or -N- (alkyl (C1-4)) 2; X is O or NH; R3 is (1-10C) alkyl, (C3-7) cycloalkyl or (C3-7) cycloalkyl- (C1-4) -, a) wherein the cycloalkyl and cycloalkyl-alkyl- may be mono-, di- or trisubstituted with (C1-3) alkyl; b) wherein the alkyl, cycloalkyl and cycloalkyl-alkyl- may be mono- or disubstituted with substituents independently selected from hydroxy and O- (C1-6) alkyl; c) wherein each alkyl group may be mono-, di- or trisubstituted by halogen; and d) wherein in each cycloalkyl group of 5, 6 or 7-membered one or two -CH2- groups not directly linked to each may be substituted by -O- such that the O-atom is linked to the group X via at least two C atoms; e) D is a saturated or unsaturated 3 to 8 atoms alkylene chain; and the dotted line "b" is a single or double bond; wherein Het as used herein, is defined as a 3- to 7-membered having 1 to 4 heteroatoms independently selected from O, N and S, which may be saturated, unsaturated or aromatic and optionally is fused to at least one other ring to form a heteropolycycle 4 to 14 members with 1 to 5 heteroatoms wherever possible, each independently selected from O, N and S, which may be saturated, unsaturated or aromatic; or a salt or pharmaceutically acceptable ester; with the proviso that R2 is a group of formula; and W is N; and the dotted line "a" is a double bond; and R20 is H, halogen or Y1-R20a, where Y1 is O and R 20a is I (1-6C) alkyl or (3-6C) cycloalkyl; or Y1 is a bond and R 20a is (1-6C) alkyl; and R21 is halogen or Y2-R21a, where Y2 is O and R 21a is (1-6C) alkyl or (3-6C) cycloalkyl; and R22 is H; and R3 is (C1-6) alkyl optionally substituted with halogen, or R3 is - (CH2) p-cycloalkyl (C3-7), where p is 0-4, or R3 is a tetrahydrofuran ring linked through its C3 position or C4; then R1 is not equal to NHSO2R11 R11 (1-6C) alkyl or (C3-7) alkyl.